Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries
Archives of Academic Emergency Medicine,
Vol. 8 No. 1 (2020),
7 January 2020
COronaVIrus Disease 2019 (COVID-19), is an ongoing pandemic attributed to a novel virus SARSâ€CoVâ€2. The statistics of the incidence and the death rates between nations reveal that there is a discrepancy amongst compared with even those that share their borders. We herein present information from the literature on how cross-protection against COVID-19 conferred by the encephalitis vaccine could be the reason for lower fatality rate in the countries where immunization against encephalitis is widespread or included in national programs. This may pave way for arriving at efficient strategies of prevention as well as vaccine development.
- Cross Immunity
- Encephalitis vaccine
How to Cite
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). StatPearls [Internet]: StatPearls Publishing; 2020.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80.
Control ECfDPa. Situation update worldwide, as of 20 April 2020 2020 [April 21, 2020]. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
Coronavirus cases have dropped sharply in South Korea. Whatâ€™s the secret to its success? 2020 [April 21, 2020]. Available from: https://www.sciencemag.org/news/2020/03/coronavirus-cases-have-dropped-sharply-south-korea-whats-secret-its-success.
What Lessons Can the US Learn from Japan and South Korea for Combating Coronavirus? 2020 [April 21, 2020]. Available from: https://globalbiodefense.com/2020/03/16/united-states-lessons-learned-covid-19-pandemic-response-south-korea-japan-observations-hyunjung-kim-gmu-biodefense.
Sone T, Nakaya N, Ohmori K, Shimazu T, Higashiguchi M, Kakizaki M, et al. Sense of life worth living (ikigai) and mortality in Japan: Ohsaki Study. Psychosomatic medicine. 2008;70(6):709-15.
Control ECfDPa. Tick-Borne Encephalitis: Recommended vaccinations 2020 [March 26, 2020]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=27&SelectedCountryIdByDisease=-1.
Talbot PJ, Desforges M, Brison E, Jacomy H, Tkachev S. Coronaviruses as encephalitis-inducing infectious agents. Non-flavirus Encephalitis In-Tech. 2011:185-202.
Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. Journal of Neurology, Neurosurgery & Psychiatry. 2000;68(4):405-15.
Li J, Gao N, Fan D, Chen H, Sheng Z, Fu S, et al. Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice. Scientific reports. 2016;6(1):1-9.
Liu B, Li NL, Wang J, Shi P-Y, Wang T, Miller MA, et al. Overlapping and distinct molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus. Journal of virology. 2014;88(23):13821-35.
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARSâ€CoV2 may play a role in the respiratory failure of COVIDâ€19 patients. Journal of medical virology. 2020.
Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2. International Journal of Infectious Diseases. 2020.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020.
- Abstract Viewed: 1906 times
- PDF Downloaded: 559 times
- HTML Downloaded: 22 times